Generation Development Group (ASX:GDG) is a company you may not be familiar with: it's only just in the ASX Top 500 and often flies under the radar of the mainstream financial press.

However, you have probably heard of its main brand GenLife, would definitely know GenLife's CEO Grant Hackett and may have seen it in the media lately as it pursues the final piece of ratings and investment house Lonsec.

In our latest podcast Lucas Goode, IML Portfolio Manager and Equities Analyst, highlights why GDG is IML's stock of the month, shedding light on:

• GDG’s unique and differentiated product offerings
• The potential Lonsec acquisition
• Recent share price appreciation and future growth potential

Around the world, many nations are preparing for the largest ever wealth transfer in history. In Australia, it is estimated around $3.5 trillion in assets will be passed on to future generations by 2050.*

So how will this intergenerational wealth transfer impact the Australian economy and society at large?

Find out in our third and final instalment of Louise Watson's interview with demographer Simon Kuestenmacher. They discuss:

• How and when wealth will transfer from baby boomers to future generations
• The changing face of retirement
• The impact it will have on the housing market
• The social and ethical considerations of “the bank of mum and dad"

*Australian Government Productivity Commission 2021 report "Wealth transfers and their economic effects"

Shareholders of ResMed have been on a rollercoaster ride in the past year. Late last year, after news of the efficacy of Ozempic and other GLP-1 drugs came to light, the ResMed share price dropped as investors grew concerned about the potential impact on ResMed’s business. But since then it has steadily made up lost ground and is now trading at similar levels.

• But what has driven the share price appreciation?
• Has the Ozempic effect hit yet?
• And does ResMed’s rally have further to go?

In our latest podcast, IML’s Senior Equity Analyst Bruce Du, gives his perspective.